Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISRADIPINE vs CADUET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Hypertension,Chronic stable angina
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Hepatic metabolism via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
96%, primarily to alpha-1-acid glycoprotein and albumin.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
2.9 L/kg (3-5 L/kg reported); clinical meaning: extensive tissue distribution, high affinity for vascular smooth muscle.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Oral: 15-24% (first-pass effect); sustained-release: approximately 30% due to reduced presystemic metabolism.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
No dose adjustment required for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate at 2.5 mg twice daily and titrate cautiously.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
For Child-Pugh Class A or B: initiate at 2.5 mg twice daily and titrate cautiously. For Child-Pugh Class C: use isradipine with caution; consider starting at 2.5 mg once daily and adjust based on response and tolerability.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Not FDA-approved for pediatric use. Limited data: initial dose 0.05-0.15 mg/kg orally 3-4 times daily; maximum 0.8 mg/kg/day.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of hypotension. Maximum dose usually 5 mg twice daily.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
None
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
May cause hypotension, peripheral edema, heart failure exacerbation (particularly in patients with pre-existing left ventricular dysfunction), and increased angina or myocardial infarction upon abrupt withdrawal. Use caution in patients with aortic stenosis, hepatic impairment, and in elderly patients. May cause gingival hyperplasia. Should be used with caution in patients with severe left ventricular dysfunction or heart failure.
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Hypersensitivity to isradipine or any dihydropyridine calcium channel blocker; cardiogenic shock; unstable angina; acute myocardial infarction (within first 4 weeks); severe aortic stenosis; second- or third-degree AV block (unless pacemaker present); sick sinus syndrome (unless pacemaker present); concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) due to increased risk of toxicity.
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase isradipine levels, leading to toxicity. High-fat meals may slow absorption but do not significantly alter overall effect. No other specific dietary restrictions.
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: potential for teratogenic effects. Second and third trimesters: may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension; also associated with decreased uterine blood flow.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Isradipine is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.14. Low concentrations are expected; based on limited data, the relative infant dose is <1% of maternal weight-adjusted dose. However, due to potential for adverse effects in nursing infants (e.g., hypotension), caution is advised. Consider benefits of breastfeeding and importance of drug to mother.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
Pregnancy may alter the pharmacokinetics of isradipine due to increased plasma volume, renal clearance, and hepatic metabolism. No specific dose adjustment guidelines are established; however, higher doses may be required to achieve therapeutic effect. Conversely, increased sensitivity to hypotensive effects may necessitate dose reduction. Individualize dosing based on blood pressure response and tolerance. Start at low doses and titrate carefully.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
Isradipine is a dihydropyridine calcium channel blocker with high vascular selectivity; it causes less negative inotropic effect than nifedipine. It is used for hypertension and has been studied for Parkinson's disease but not FDA-approved for that indication. Its short half-life (8 hours) necessitates twice-daily dosing. Monitor for peripheral edema, headache, and dizziness. Avoid grapefruit juice as it increases drug levels. Use with caution in patients with aortic stenosis or heart failure with reduced ejection fraction.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Take this medication exactly as prescribed, usually twice daily.,Do not drink grapefruit juice while taking isradipine.,Avoid sudden discontinuation; consult your doctor before stopping.,Common side effects include swelling of ankles/feet, headache, and dizziness; report severe or persistent symptoms.,This medicine does not cure hypertension but helps control it; continue taking even if you feel well.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
"The combination of isradipine, a dihydropyridine calcium channel blocker, with propranolol, a non-selective beta-blocker, can result in additive negative chronotropic and inotropic effects, leading to excessive bradycardia, hypotension, and potentially heart failure. Additionally, propranolol may mask the reflex tachycardia typically induced by isradipine's vasodilation, blunting compensatory mechanisms and increasing the risk of severe hypotension. Careful monitoring and dose adjustments are necessary when coadministering these agents."
"Isradipine, a calcium channel blocker, inhibits CYP3A4-mediated metabolism of saquinavir, a protease inhibitor used in HIV therapy. This leads to significantly increased saquinavir plasma concentrations, raising the risk of dose-related toxicities such as hepatotoxicity, QT prolongation, and gastrointestinal disturbances. Conversely, saquinavir may also inhibit isradipine metabolism, potentially causing enhanced hypotensive effects and peripheral edema."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISRADIPINE vs CADUET, answered by our medical review team.
ISRADIPINE is a Calcium Channel Blocker that works by Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.. CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISRADIPINE and CADUET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISRADIPINE is: 2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.. The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISRADIPINE and CADUET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISRADIPINE is classified as Category C. Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recomme. CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.